AstraZeneca AB & Anor v Apotex Pty Ltd; AstraZeneca AB & Anor v Watson Pharma Pty Ltd; AstraZeneca AB & Anor v Ascent Pharma Pty Ltd

AstraZeneca AB and AstraZeneca Pty Ltd (the applicants) brought proceedings against Apotex Pty Ltd, Watson Pharma Pty Ltd, and Ascent Pharma Pty Ltd (the respondents) concerning alleged infringement of AstraZeneca's patent for a pharmaceutical product. The dispute centred on the respondents' proposed or actual importation and sale of generic versions of the drug rosuvastatin, which AstraZeneca claimed infringed its patent rights. The matter proceeded to the High Court of Australia.

The High Court was required to determine, among other things, whether the respondents' proposed or actual importation and sale of generic rosuvastatin constituted infringement of AstraZeneca's patent. This involved considering the scope of the patent claims and whether the respondents' products fell within that scope, as well as the application of relevant provisions of the *Patents Act 1990* (Cth) concerning infringement and defences.

The Court's reasoning focused on the construction of the patent claims and the evidence presented regarding the respondents' products. It applied established principles of patent law, including the approach to claim construction and the assessment of infringement. The Court considered whether the respondents' products were equivalent to the patented invention, taking into account the doctrine of equivalents and the specific wording of the patent claims. The Court also examined the validity of the patent in light of arguments raised by the respondents.

The High Court ultimately found that the respondents had infringed AstraZeneca's patent. Consequently, orders were made granting injunctions and other relief in favour of AstraZeneca.